

Dan V Iosifescu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3598594/publications.pdf>

Version: 2024-02-01

200
papers

14,061
citations

28242

55
h-index

22808

112
g-index

206
all docs

206
docs citations

206
times ranked

15475
citing authors

#	ARTICLE	IF	CITATIONS
1	Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes. Australian and New Zealand Journal of Psychiatry, 2023, 57, 93-103.	1.3	3
2	Correlation between S100B and severity of depression in MDD: A meta-analysis. World Journal of Biological Psychiatry, 2022, 23, 456-463.	1.3	12
3	Cardiomatabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response. Journal of Affective Disorders, 2022, 300, 41-49.	2.0	6
4	Affective and somatic symptom clusters in depression and their relationship to treatment outcomes in the STAR*D sample. Journal of Affective Disorders, 2022, 300, 469-473.	2.0	2
5	Imbalance between default mode and sensorimotor connectivity is associated with perseverative thinking in obsessive-compulsive disorder. Translational Psychiatry, 2022, 12, 19.	2.4	9
6	Relationships between interoceptive sensibility and resting-state functional connectivity of the insula in obsessive-compulsive disorder. Cerebral Cortex, 2022, 32, 5285-5300.	1.6	7
7	Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. American Journal of Psychiatry, 2022, 179, 490-499.	4.0	46
8	Pharmacogenomic Testing for Next-Step Antidepressant Selection. JAMA - Journal of the American Medical Association, 2022, 328, 146.	3.8	6
9	A systematic review and network meta-analysis of carbon dioxide provocation in psychiatric disorders. Journal of Psychiatric Research, 2021, 143, 508-515.	1.5	4
10	Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials. Depression and Anxiety, 2021, 38, 114-123.	2.0	5
11	Combined effects of genotype and childhood adversity shape variability of DNA methylation across age. Translational Psychiatry, 2021, 11, 88.	2.4	27
12	Influences on childhood depressive symptoms: The effects of trauma and distress tolerance across age and sex groups. Journal of Affective Disorders, 2021, 283, 373-376.	2.0	3
13	Rapid Effects of AXS-05, an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: Results From Two Randomized, Double-Blind, Controlled Trials. Biological Psychiatry, 2021, 89, S244.	0.7	1
14	Insula Functional Connectivity During Urge Suppression in Obsessive-Compulsive Disorder. Biological Psychiatry, 2021, 89, S241.	0.7	0
15	Urges-For-Action in OCD: Blink Suppression Failure Relates to Clinical Heterogeneity. Biological Psychiatry, 2021, 89, S132.	0.7	0
16	Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. American Journal of Psychiatry, 2021, 178, 437-446.	4.0	33
17	Neural Mechanisms of Symptom Dimensions During Provocation in Obsessive-Compulsive Disorder. Biological Psychiatry, 2021, 89, S361-S362.	0.7	0
18	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Focus (American) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.4	9

#	ARTICLE	IF	CITATIONS
19	The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. <i>European Neuropsychopharmacology</i> , 2021, 49, 122-132.	0.3	17
20	Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response. <i>Psychiatry Research</i> , 2021, 305, 114194.	1.7	1
21	Differential reinforcement learning responses to positive and negative information in unmedicated individuals with depression. <i>European Neuropsychopharmacology</i> , 2021, 53, 89-100.	0.3	12
22	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , 2020, 25, 1592-1603.	4.1	235
23	Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. <i>Molecular Psychiatry</i> , 2020, 25, 1323-1333.	4.1	40
24	Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients. <i>Psychophysiology</i> , 2020, 57, e13356.	1.2	19
25	Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2020, 260, 131-139.	2.0	21
26	Dimensions of interoception in obsessive-compulsive disorder. <i>Journal of Obsessive-Compulsive and Related Disorders</i> , 2020, 27, 100584.	0.7	8
27	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. <i>Frontiers in Psychiatry</i> , 2020, 11, 595584.	1.3	143
28	Are Electroencephalogram-Derived Predictors of Antidepressant Efficacy Closer to Clinical Usefulness?. <i>JAMA Network Open</i> , 2020, 3, e207133.	2.8	3
29	Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). <i>Neuropsychopharmacology</i> , 2020, 45, 1656-1663.	2.8	50
30	A randomized proof-of-mechanism trial applying the "fast-fail" approach to evaluating μ -opioid antagonism as a treatment for anhedonia. <i>Nature Medicine</i> , 2020, 26, 760-768.	15.2	129
31	Plasma Neuronal and Glial Markers and Anterior Cingulate Metabolite Levels in Major Depressive Disorder: A Pilot Study. <i>Neuropsychobiology</i> , 2020, 79, 214-221.	0.9	24
32	Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression. <i>Brain</i> , 2020, 143, 701-710.	3.7	56
33	The buildup of an urge in obsessive-compulsive disorder: Behavioral and neuroimaging correlates. <i>Human Brain Mapping</i> , 2020, 41, 1611-1625.	1.9	11
34	Glutamate Modulators in Major Depressive Disorder. , 2020, , 169-174.		0
35	Neuropeptide Y in PTSD, MDD, and chronic stress: A systematic review and meta-analysis. <i>Journal of Neuroscience Research</i> , 2020, 98, 950-963.	1.3	32
36	Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response. <i>Journal of Affective Disorders</i> , 2020, 273, 131-137.	2.0	7

#	ARTICLE	IF	CITATIONS
37	Efficacy of Esketamine Augmentation in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	71
38	Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 539-547.	0.3	4
39	Protein Biomarkers in Major Depressive Disorder: An Update. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1140, 585-600.	0.8	5
40	Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. <i>Journal of Psychiatric Research</i> , 2019, 110, 166-171.	1.5	41
41	Reported Side Effects, Weight and Blood Pressure, After Repeated Sessions of Transcranial Photobiomodulation. <i>Photobiomodulation, Photomedicine, and Laser Surgery</i> , 2019, 37, 651-656.	0.7	28
42	116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective μ -Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients. <i>Biological Psychiatry</i> , 2019, 85, S48-S49.	0.7	0
43	Initial Evidence for Brain Plasticity Following a Digital Therapeutic Intervention for Depression. <i>Chronic Stress</i> , 2019, 3, 247054701987788.	1.7	2
44	S198. Effects of Transcranial Photobiomodulation With Near-Infrared Light on Sexual Dysfunction. <i>Biological Psychiatry</i> , 2019, 85, S374.	0.7	0
45	Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials. <i>Acta Neuropsychiatrica</i> , 2019, 31, 230-234.	1.0	2
46	F85. Reported Side-Effects, Weight and Blood Pressure After Repeated Sessions of Transcranial Photobiomodulation. <i>Biological Psychiatry</i> , 2019, 85, S245.	0.7	1
47	Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. <i>Neuropsychopharmacology</i> , 2019, 44, 1812-1819.	2.8	32
48	Neural Predictors of the Antidepressant Placebo Response. <i>Pharmaceuticals</i> , 2019, 12, 158.	1.7	1
49	<p>Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 3255-3272.	1.0	35
50	Effects of transcranial photobiomodulation with near-infrared light on sexual dysfunction. <i>Lasers in Surgery and Medicine</i> , 2019, 51, 127-135.	1.1	18
51	Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. <i>Depression and Anxiety</i> , 2019, 36, 235-243.	2.0	37
52	The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 82-84.	21.5	52
53	251. Dopamine Release in Treatment-Naïve Major Depressive Disorder: A [11C]-(+)-PHNO Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2018, 83, S101.	0.7	0
54	252. Major Depressive Disorder is Associated With Blunted Learning Signals in Medial Prefrontal Cortex and Putamen When Seeking Monetary Reward. <i>Biological Psychiatry</i> , 2018, 83, S101-S102.	0.7	0

#	ARTICLE	IF	CITATIONS
55	A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. <i>Journal of Affective Disorders</i> , 2018, 230, 56-64.	2.0	36
56	Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 200-206.	0.7	13
57	Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). <i>Brain Stimulation</i> , 2018, 11, 75-84.	0.7	20
58	Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2018, 30, 297-305.	1.0	10
59	A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 336-343.	0.7	0
60	The Influence of Depression on the Psychometric Properties of the Maslach Burnout Inventoryâ€”Human Services Survey: A Cross-Sectional Study With Nursing Assistants. <i>Frontiers in Psychiatry</i> , 2018, 9, 695.	1.3	15
61	DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder. <i>Clinical Epigenetics</i> , 2018, 10, 136.	1.8	36
62	253. Utilizing a Behavioral Assay of Reward Learning to Predict Clinical Response to a Dopamine Agonist in Individuals With Depression. <i>Biological Psychiatry</i> , 2018, 83, S102.	0.7	1
63	Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial. <i>Photomedicine and Laser Surgery</i> , 2018, 36, 634-646.	2.1	73
64	Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study. <i>Biological Psychiatry</i> , 2018, 84, 563-573.	0.7	31
65	A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression. <i>Npj Digital Medicine</i> , 2018, 1, .	5.7	16
66	F179. Epigenetic Biomarkers in Women With Posttraumatic Stress Disorder After CRF1 Receptor Antagonist Treatment. <i>Biological Psychiatry</i> , 2018, 83, S308.	0.7	0
67	A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 3-11.	1.0	56
68	White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 355-365.	1.3	22
69	Ketamine and ECT: better alone than together?. <i>Lancet Psychiatry</i> , 2017, 4, 348-349.	3.7	15
70	Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial. <i>Journal of Affective Disorders</i> , 2017, 218, 277-283.	2.0	41
71	549. DNA Methylation Biomarkers and Treatment Effects of a Corticotropin Releasing Hormone Type 1 Receptor Antagonist in a Biologically-Defined Subset of PTSD-Patients. <i>Biological Psychiatry</i> , 2017, 81, S222.	0.7	1
72	A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy. <i>Journal of Psychopharmacology</i> , 2017, 31, 1190-1203.	2.0	10

#	ARTICLE	IF	CITATIONS
73	525. The Temporal Stability of Cognitive Functioning and Functional Capacity in Women with PTSD. <i>Biological Psychiatry</i> , 2017, 81, S213.	0.7	0
74	171. A Randomized Controlled Dose-Ranging Study of Intranasal Administration of Neuropeptide Y in Patients with Posttraumatic Stress Disorder. <i>Biological Psychiatry</i> , 2017, 81, S71.	0.7	1
75	Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. <i>Biological Psychiatry</i> , 2017, 82, 866-874.	0.7	74
76	Tissue Type-Specific Bioenergetic Abnormalities in Adults with Major Depression. <i>Neuropsychopharmacology</i> , 2017, 42, 876-885.	2.8	51
77	Ketamine Treatment and Global Brain Connectivity in Major Depression. <i>Neuropsychopharmacology</i> , 2017, 42, 1210-1219.	2.8	240
78	The influence of depression on personality traits in patients with fibromyalgia: a case-control study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 13-19.	0.4	2
79	The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 2131-2142.	1.0	15
80	Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. <i>Human Brain Mapping</i> , 2016, 37, 3214-3223.	1.9	125
81	Ketamine for treatment-resistant depression: recent developments and clinical applications: Table 1. <i>Evidence-Based Mental Health</i> , 2016, 19, 35-38.	2.2	102
82	Using Placebo Response to Pain as a Predictor of Placebo Response in Mood Disorders. <i>Current Behavioral Neuroscience Reports</i> , 2016, 3, 360-367.	0.6	1
83	Chapter 40 Transcranial Near-Infrared Light for Major Depressive Disorder. , 2016, , 809-824.		0
84	Using Electroencephalography for Treatment Guidance in Major Depressive Disorder. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2016, 1, 411-422.	1.1	43
85	Review of transcranial photobiomodulation for major depressive disorder: targeting brain metabolism, inflammation, oxidative stress, and neurogenesis. <i>Neurophotonics</i> , 2016, 3, 031404.	1.7	136
86	The association of post-stroke anhedonia with salivary cortisol levels and stroke lesion in hippocampal/parahippocampal region. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 233.	1.0	15
87	Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study. <i>Psychiatry Journal</i> , 2015, 2015, 1-8.	0.7	90
88	Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial. <i>Neuropsychopharmacology</i> , 2015, 40, 1084-1090.	2.8	117
89	Illness Progression, Recent Stress, and Morphometry of Hippocampal Subfields and Medial Prefrontal Cortex in Major Depression. <i>Biological Psychiatry</i> , 2015, 77, 285-294.	0.7	267
90	The Influence of Depressive Symptoms on Quality of Life after Stroke: A Prospective Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 201-209.	0.7	35

#	ARTICLE	IF	CITATIONS
91	The promise of ketamine for treatment-resistant depression: current evidence and future directions. <i>Annals of the New York Academy of Sciences</i> , 2015, 1345, 47-58.	1.8	70
92	Lithium Treatment Moderate-Dose Use Study (LiTMUS) for Bipolar Disorder: A Randomized Comparative Effectiveness Trial of Optimized Personalized Treatment With and Without Lithium. <i>Focus (American Journal of Psychiatry)</i> , 2015, 134, 101-107.	0.8	10
93	Anhedonia in melancholic and non-melancholic depressive disorders. <i>Journal of Affective Disorders</i> , 2015, 184, 81-88.	2.0	53
94	Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. <i>Brain Stimulation</i> , 2015, 8, 787-794.	0.7	145
95	In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature. <i>Annals of the New York Academy of Sciences</i> , 2015, 1344, 50-65.	1.8	80
96	An exploratory study of responses to low-dose lithium in African Americans and Hispanics. <i>Journal of Affective Disorders</i> , 2015, 178, 224-228.	2.0	9
97	A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR). <i>Journal of Psychiatric Research</i> , 2015, 71, 126-133.	1.5	32
98	Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 247-252.	1.1	179
99	Maintaining the Initial Clinical Response After Ketamine in Bipolar and Unipolar Depression: An Important Next-Step Challenge. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 738-740.	1.1	6
100	The effect of personalized guideline-concordant treatment on quality of life and functional impairment in bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 169, 144-148.	2.0	15
101	Limbic system white matter microstructure and long-term treatment outcome in major depressive disorder: A diffusion tensor imaging study using legacy data. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 122-134.	1.3	43
102	COGNITIVE-EMOTIONAL TRAINING AS AN INTERVENTION FOR MAJOR DEPRESSIVE DISORDER. <i>Depression and Anxiety</i> , 2014, 31, 699-706.	2.0	58
103	EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION. <i>Depression and Anxiety</i> , 2014, 31, 335-343.	2.0	275
104	Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder. <i>JAMA Psychiatry</i> , 2014, 71, 681.	6.0	466
105	A novel application of the <i>Intent to Attend</i> assessment to reduce bias due to missing data in a randomized controlled clinical trial. <i>Clinical Trials</i> , 2014, 11, 494-502.	0.7	9
106	Executive function and depressive symptoms of retardation in nonelderly stroke patients. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2014, 36, 636-647.	0.8	4
107	Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. <i>Psychopharmacology</i> , 2014, 231, 481-488.	1.5	73
108	Tissue-Specific Differences in Brain Phosphodiesterases in Late-Life Major Depression. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 499-509.	0.6	18

#	ARTICLE	IF	CITATIONS
109	Pilot investigation of isradipine in the treatment of bipolar depression motivated by genome-wide association. <i>Bipolar Disorders</i> , 2014, 16, 199-203.	1.1	45
110	Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: Examining the convergence of performance-based measures and self-reports. <i>Journal of Psychiatric Research</i> , 2014, 57, 51-57.	1.5	35
111	Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 240.	0.7	41
112	Biomarkers in Major Depressive Disorder: The Role of Mass Spectrometry. <i>Advances in Experimental Medicine and Biology</i> , 2014, 806, 545-560.	0.8	13
113	A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2014, 76, 970-976.	0.7	369
114	Rare Copy Number Variation in Treatment-Resistant Major Depressive Disorder. <i>Biological Psychiatry</i> , 2014, 76, 536-541.	0.7	67
115	Feasibility of studying brain morphology in major depressive disorder with structural magnetic resonance imaging and clinical data from the electronic medical record: A pilot study. <i>Psychiatry Research - Neuroimaging</i> , 2013, 211, 202-213.	0.9	12
116	Lithium Treatment Moderate-Dose Use Study (LiTMUS) for Bipolar Disorder: A Randomized Comparative Effectiveness Trial of Optimized Personalized Treatment With and Without Lithium. <i>American Journal of Psychiatry</i> , 2013, 170, 102-110.	4.0	80
117	Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression. <i>Biological Psychiatry</i> , 2013, 74, 250-256.	0.7	632
118	The Medication Recommendation Tracking Form: A novel tool for tracking changes in prescribed medication, clinical decision making, and use in comparative effectiveness research. <i>Journal of Psychiatric Research</i> , 2013, 47, 1686-1693.	1.5	14
119	A mega-analysis of genome-wide association studies for major depressive disorder. <i>Molecular Psychiatry</i> , 2013, 18, 497-511.	4.1	1,002
120	Use of Treatment Services in a Comparative Effectiveness Study of Bipolar Disorder. <i>Psychiatric Services</i> , 2013, 64, 1119-1126.	1.1	3
121	Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2013, 170, 1134-1142.	4.0	965
122	QT interval and antidepressant use: a cross sectional study of electronic health records. <i>BMJ</i> , The, 2013, 346, f288-f288.	3.0	252
123	Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 26-42.	1.3	61
124	Quantitative Electroencephalogram Biomarkers for Predicting Likelihood and Speed of Achieving Sustained Remission in Major Depression. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 51-56.	1.1	26
125	A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2013, 74, e636-e641.	1.1	70
126	Depression: Diagnosis and Treatment. , 2013, , 949-961.		0

#	ARTICLE	IF	CITATIONS
127	Methods to limit attrition in longitudinal comparative effectiveness trials: lessons from the Lithium Treatment “Moderate dose Use Study (LiTMUS) for bipolar disorder. <i>Clinical Trials</i> , 2012, 9, 94-101.	0.7	11
128	Antidepressant Response in Patients With Major Depression Exposed to NSAIDs: A Pharmacovigilance Study. <i>American Journal of Psychiatry</i> , 2012, 169, 1065-1072.	4.0	70
129	A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study). <i>Psychotherapy and Psychosomatics</i> , 2012, 81, 87-97.	4.0	122
130	Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. <i>BMJ Open</i> , 2012, 2, e000544.	0.8	44
131	Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. <i>CNS Spectrums</i> , 2012, 17, 76-86.	0.7	15
132	The relation between mood, cognition and psychosocial functioning in psychiatric disorders. <i>European Neuropsychopharmacology</i> , 2012, 22, S499-S504.	0.3	63
133	Measuring severe adverse events and medication selection using a “PEER Report” for nonpsychotic patients: a retrospective chart review. <i>Neuropsychiatric Disease and Treatment</i> , 2012, 8, 277.	1.0	1
134	Stroke lesion in cortical neural circuits and post-stroke incidence of major depressive episode: A 4-month prospective study. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 539-548.	1.3	87
135	Diagnosis and Treatment of Major Depressive Disorder. <i>Neurologic Clinics</i> , 2011, 29, 177-193.	0.8	37
136	Cognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies. <i>Neurobiology of Learning and Memory</i> , 2011, 96, 553-563.	1.0	264
137	The association of major depressive episode and personality traits in patients with fibromyalgia. <i>Clinics</i> , 2011, 66, 973-978.	0.6	22
138	Retrospective chart review of a referenced EEG database in assisting medication selection for treatment of depression in patients with eating disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 529.	1.0	6
139	Polypharmacy or medication washout: an old tool revisited. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 639.	1.0	17
140	The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. <i>Journal of Psychiatric Research</i> , 2011, 45, 64-75.	1.5	42
141	Electroencephalography-Derived Biomarkers of Antidepressant Response. <i>Harvard Review of Psychiatry</i> , 2011, 19, 144-154.	0.9	109
142	A Post Hoc Analysis of the Effect of Nightly Administration of Eszopiclone and a Selective Serotonin Reuptake Inhibitor in Patients With Insomnia and Anxious Depression. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 473-479.	1.1	34
143	Relationship Between Residual Symptoms of Depression and Self-reported Cognitive Impairment. <i>CNS Spectrums</i> , 2010, 15, 46-51.	0.7	20
144	Age-related changes in brain energetics and phospholipid metabolism. <i>NMR in Biomedicine</i> , 2010, 23, 242-250.	1.6	78

#	ARTICLE	IF	CITATIONS
145	Prevalence of Incompletely Penetrant Huntington's Disease Alleles Among Individuals With Major Depressive Disorder. <i>American Journal of Psychiatry</i> , 2010, 167, 574-579.	4.0	45
146	RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 322-325.	1.9	122
147	GABA α Receptor Modulators: Can they Offer any Improvement over Benzodiazepines in the Treatment of Anxiety Disorders?. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 61-62.	1.9	2
148	Microstructural Abnormalities in Subcortical Reward Circuitry of Subjects with Major Depressive Disorder. <i>PLoS ONE</i> , 2010, 5, e13945.	1.1	112
149	Importance of retardation and fatigue/interest domains for the diagnosis of major depressive episode after stroke: a four months prospective study. <i>Revista Brasileira De Psiquiatria</i> , 2009, 31, 202-207.	0.9	12
150	Lithium treatment "moderate dose use study (LiTMUS) for bipolar disorder: rationale and design. <i>Clinical Trials</i> , 2009, 6, 637-648.	0.7	39
151	Reliability and Validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire. <i>Psychotherapy and Psychosomatics</i> , 2009, 78, 91-97.	4.0	114
152	Reduced Caudate and Nucleus Accumbens Response to Rewards in Unmedicated Individuals With Major Depressive Disorder. <i>American Journal of Psychiatry</i> , 2009, 166, 702-710.	4.0	1,003
153	Recognition of Depressive Symptoms by Physicians. <i>Clinics</i> , 2009, 64, 629-635.	0.6	17
154	A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: The relevance of the placebo effect and psychological symptoms. <i>Contemporary Clinical Trials</i> , 2009, 30, 205-211.	0.8	48
155	Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. <i>Psychiatry Research</i> , 2009, 169, 132-138.	1.7	109
156	Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: Results of the BRITE-MD study. <i>Psychiatry Research</i> , 2009, 169, 124-131.	1.7	162
157	Frontal EEG predictors of treatment outcome in major depressive disorder. <i>European Neuropsychopharmacology</i> , 2009, 19, 772-777.	0.3	158
158	Galantamine "For Cognitive Dysfunction In Bipolar Disorder and Correlation with Hippocampal Neuronal Viability: A Proof of Concept Study. <i>CNS Neuroscience and Therapeutics</i> , 2009, 15, 309-319.	1.9	41
159	Low-dose Transdermal Testosterone Augmentation Therapy Improves Depression Severity in Women. <i>CNS Spectrums</i> , 2009, 14, 688-694.	0.7	52
160	Neuroimaging and Electrophysiology Studies in Major Depressive Disorder. <i>Medical Psychiatry</i> , 2009, , 150-165.	0.2	0
161	Clinical applications of neuroimaging for treating depressive disorders. <i>Psychiatry</i> , 2009, 6, 49-51.	0.3	0
162	Reduced hedonic capacity in major depressive disorder: Evidence from a probabilistic reward task. <i>Journal of Psychiatric Research</i> , 2008, 43, 76-87.	1.5	613

#	ARTICLE	IF	CITATIONS
163	Brain Bioenergetics and Response to Triiodothyronine Augmentation in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2008, 63, 1127-1134.	0.7	152
164	Euthymic Patients with Bipolar Disorder Show Decreased Reward Learning in a Probabilistic Reward Task. <i>Biological Psychiatry</i> , 2008, 64, 162-168.	0.7	157
165	Cortical Thickness Abnormalities in Cocaine Addiction—A Reflection of Both Drug Use and a Pre-existing Disposition to Drug Abuse?. <i>Neuron</i> , 2008, 60, 174-188.	3.8	150
166	Prediction of Response to Antidepressants: Is Quantitative EEG (QEEG) an Alternative?. <i>CNS Neuroscience and Therapeutics</i> , 2008, 14, 263-265.	1.9	13
167	Major Depressive Disorder With Anger Attacks and Subcortical MRI White Matter Hyperintensities. <i>Journal of Nervous and Mental Disease</i> , 2007, 195, 175-178.	0.5	24
168	Major Depressive Disorder with Anger Attacks and Cardiovascular Risk Factors. <i>International Journal of Psychiatry in Medicine</i> , 2007, 37, 99-111.	0.8	16
169	Autonomic reactivity to induced emotion as potential predictor of response to antidepressant treatment. <i>Psychiatry Research</i> , 2007, 151, 169-172.	1.7	43
170	Major Depressive Disorder and Comorbid Cardiac Disease: Is There a Depressive Subtype With Greater Cardiovascular Morbidity? Results From the STAR*D Study. <i>Psychosomatics</i> , 2007, 48, 418-425.	2.5	30
171	Treating Depression in the Medically Ill. <i>Psychiatric Clinics of North America</i> , 2007, 30, 77-90.	0.7	40
172	Major Depressive Disorder and Inflammatory Markers in Elderly Patients With Heart Failure. <i>Psychosomatics</i> , 2007, 48, 319-324.	2.5	21
173	Clinical characteristics of depressed patients with comorbid diabetes mellitus. <i>International Clinical Psychopharmacology</i> , 2006, 21, 43-47.	0.9	6
174	Brain white-matter hyperintensities and treatment outcome in major depressive disorder. <i>British Journal of Psychiatry</i> , 2006, 188, 180-185.	1.7	59
175	The detection of depression in medical setting: A study with PRIME-MD. <i>Journal of Affective Disorders</i> , 2006, 91, 11-17.	2.0	74
176	The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. <i>Depression and Anxiety</i> , 2006, 23, 178-181.	2.0	45
177	A Cross-Sectional Study of the Prevalence of Cognitive and Physical Symptoms During Long-Term Antidepressant Treatment. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1754-1759.	1.1	181
178	Empirical Testing of Two Models for Staging Antidepressant Treatment Resistance. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 336-341.	0.7	96
179	Cardiovascular Risk Factors May Moderate Pharmacological Treatment Effects in Major Depressive Disorder. <i>Psychosomatic Medicine</i> , 2005, 67, 703-706.	1.3	55
180	Obesity among outpatients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 59-63.	1.0	89

#	ARTICLE	IF	CITATIONS
181	Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). <i>Psychiatry Research - Neuroimaging</i> , 2005, 140, 301-307.	0.9	35
182	Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I). <i>Psychiatry Research - Neuroimaging</i> , 2005, 140, 291-299.	0.9	28
183	The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder. <i>Focus (American Journal of Psychiatry)</i> , 2005, 113, 111-117.	1.0	14
184	Tridimensional Personality Questionnaire Factors in Major Depressive Disorder: Relationship to Anxiety Disorder Comorbidity and Age of Onset. <i>Psychotherapy and Psychosomatics</i> , 2005, 74, 173-178.	4.0	40
185	An Open Study of Triiodothyronine Augmentation of Selective Serotonin Reuptake Inhibitors in Treatment-Resistant Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1038-1042.	1.1	53
186	Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. <i>Current Psychiatry Reports</i> , 2004, 6, 193-201.	2.1	57
187	Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. <i>European Neuropsychopharmacology</i> , 2004, 14, 135-142.	0.3	118
188	Effect of Medical Comorbidity on Response to Fluoxetine Augmentation or Dose Increase in Outpatients With Treatment-Resistant Depression. <i>Psychosomatics</i> , 2004, 45, 224-229.	2.5	25
189	Comorbid Medical Illness and Relapse of Major Depressive Disorder in the Continuation Phase of Treatment. <i>Psychosomatics</i> , 2004, 45, 419-425.	2.5	48
190	Serum Cholesterol in the Continuation Phase of Pharmacotherapy With Fluoxetine in Remitted Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 467-469.	0.7	10
191	Somatic Symptoms as Predictors of Time to Onset of Response to Fluoxetine in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 543-546.	1.1	30
192	Biological predictors of treatment response in affective illness. <i>Psychiatric Clinics of North America</i> , 2003, 26, 323-344.	0.7	8
193	Axis III disorders in treatment-resistant major depressive disorder. <i>Psychiatry Research</i> , 2003, 118, 183-188.	1.7	26
194	Serum Cholesterol in Treatment-Resistant Depression. <i>Neuropsychobiology</i> , 2003, 47, 146-151.	0.9	41
195	³¹ P-Magnetic Resonance Spectroscopy and Thyroid Hormones in Major Depressive Disorder: Toward a Bioenergetic Mechanism in Depression?. <i>Harvard Review of Psychiatry</i> , 2003, 11, 51-63.	0.9	23
196	The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder. <i>American Journal of Psychiatry</i> , 2003, 160, 2122-2127.	4.0	109
197	³¹ P-Magnetic Resonance Spectroscopy and Thyroid Hormones in Major Depressive Disorder: Toward a Bioenergetic Mechanism in Depression?. <i>Harvard Review of Psychiatry</i> , 2003, 11, 51-63.	0.9	25
198	T3 Blood Levels and Treatment Outcome in Depression. <i>International Journal of Psychiatry in Medicine</i> , 2001, 31, 367-373.	0.8	12

#	ARTICLE	IF	CITATIONS
199	An Automated Registration Algorithm for Measuring MRI Subcortical Brain Structures. NeuroImage, 1997, 6, 13-25.	2.1	134
200	Parcellation of the human prefrontal cortex using MRI. Psychiatry Research - Neuroimaging, 1997, 76, 29-40.	0.9	49